Telix Pharmaceuticals (TLX) Current Assets (2023 - 2025)

Telix Pharmaceuticals (TLX) has disclosed Current Assets for 3 consecutive years, with $330.3 million as the latest value for Q4 2025.

  • Quarterly Current Assets fell 45.02% to $330.3 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $330.3 million through Dec 2025, down 45.02% year-over-year, with the annual reading at $330.3 million for FY2025, 42.07% down from the prior year.
  • Current Assets for Q4 2025 was $330.3 million at Telix Pharmaceuticals, down from $600.7 million in the prior quarter.
  • The five-year high for Current Assets was $600.7 million in Q4 2024, with the low at $151.4 million in Q4 2023.
  • Average Current Assets over 3 years is $360.8 million, with a median of $330.3 million recorded in 2025.
  • The sharpest move saw Current Assets surged 296.87% in 2024, then tumbled 45.02% in 2025.
  • Over 3 years, Current Assets stood at $151.4 million in 2023, then soared by 296.87% to $600.7 million in 2024, then crashed by 45.02% to $330.3 million in 2025.
  • According to Business Quant data, Current Assets over the past three periods came in at $330.3 million, $600.7 million, and $151.4 million for Q4 2025, Q4 2024, and Q4 2023 respectively.